BENEFITS OF HIGH-FLOW NASAL OXYGEN THERAPY IN ACUTE HEART FAILURE
DOI:
https://doi.org/10.47144/phj.v55i1.2113Abstract
Acute heart failure (AHF) is a life-threatening condition. The majority of patients come to the emergency room (ER) with pulmonary congestion and respiratory failure. Therefore, oxygen therapy is an essential modality in AHF apart from diuretics and improving hemodynamic. Non-invasive ventilation (NIV) is often required to reduce hypercapnia, acidosis, and respiratory rate in AHF. However, it is more invasive than conventional oxygen therapy. NIV is also less comfortable for patients and has limited use in the ER. The high-flow nasal oxygen (HFNO) is increasing in popularity during the COVID-19 pandemic. HFNO can deliver high flow oxygen with a constant fraction in patients with respiratory failure. Studies have reported the benefits of HFNO in acute heart failure. Therefore, HFNO may benefit and may be used as an alternative to acute heart failure patients who cannot tolerate NIV.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
When an article is accepted for publication in the print format, the author will be required to transfer exclusive copyright to the PHJ and retain the rights to use and share their published article with others. However, re-submission of the full article or any part for publication by a third party would require prior permission of the PHJ.
Online publication will allow the author to retain the copyright and share the article under the agreement described in the licensing rights with creative commons, with appropriate attribution to PHJ. Creative Commons attribution license CC BY 4.0 is applied to articles published in PHJ https://creativecommons.org/licenses/by/4.0/